Diabetes · SGLT2 InhibitorRegulatory Approvalcompetitivemid-term

FDA Submission for Dapagliflozin by Jiangsu Hansoh Pharma

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/6/2026, 12:00:40 AM

Assessment confidence: 77% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The submission of Dapagliflozin by Jiangsu Hansoh Pharma represents a significant competitive move in the SGLT2 inhibitor market. This could disrupt existing market dynamics and necessitate strategic adjustments from established players to maintain their market positions. Regulatory context from FDA (FDA TA — DAPAGLIFLOZIN (ORIG)) supports the near-term read. Assessment grounded in 16 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this submission on market dynamics and consider strategic responses to new entrants. The strongest clinical anchor is STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease (ClinicalTrials.gov), entity match (dapagliflozin). In Diabetes · SGLT2 Inhibitor, 8 regulatory and 1 competitive items passed relevance filtering for Jiangsu Hansoh Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Issues Guidance on Postapproval Pregnancy Safety Studies (Humanexa Signals) — moderate corpus alignment. This submission indicates Jiangsu Hansoh's entry into the SGLT2 inhibitor market, potentially increasing competition against established players.

Regulatory Outlook

Regulatory risk is concentrated around FDA TA — DAPAGLIFLOZIN (ORIG) (FDA). Entity match (dapagliflozin); Regulatory pathway relevance (nda). The submission is currently under standard review, which could influence the approval timeline and market entry strategies for competitors.

Key Risks

Elevated medium regulatory exposure for Jiangsu Hansoh Pharma could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease) could weigh on Jiangsu Hansoh Pharma through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The entry of Jiangsu Hansoh Pharma could lead to increased competition, potentially impacting market share and pricing strategies for existing SGLT2 inhibitors.
Portfolio teams should assess the impact of this submission on market dynamics and consider strategic responses to new entrants.

What Would Change This Assessment

This becomes more urgent if Monitor the review progress and any subsequent approval outcomes for ANDA216119.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA TA — DAPAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (dapagliflozin); Regulatory pathway relevance (nda)
FDA AP — DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (dapagliflozin); Regulatory pathway relevance (nda)
FDA AP — DAPAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (dapagliflozin); Regulatory pathway relevance (nda)
FDA AP — DAPAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (dapagliflozin); Regulatory pathway relevance (nda)
FDA AP — DAPAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (dapagliflozin); Regulatory pathway relevance (nda)
FDA TA — DAPAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (dapagliflozin); Regulatory pathway relevance (nda)
FDA TA — DAPAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (dapagliflozin); Regulatory pathway relevance (nda)
FDA AP — DAPAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (dapagliflozin); Regulatory pathway relevance (nda)

STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
ClinicalTrials.govhigh relevance
Entity match (dapagliflozin)
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 t
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck)
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
Non-Pharmacological Methods in Heel Lance
ClinicalTrials.govmedium relevance
Moderate corpus alignment
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
ClinicalTrials.govmedium relevance
Moderate corpus alignment

FDA Issues Guidance on Postapproval Pregnancy Safety Studies
Humanexa Signalsmedium relevance
Moderate corpus alignment

Discovery of azaindole/indole-fused pyrimidine tetracyclic scaffolds as novel potent CDK7 inhibitors.
PubMedmedium relevance
Moderate corpus alignment
Systematic identification of bacterial neuraminidase inhibitors from Psoralea corylifolia using ultrafiltration-UPLC-Q-Orbitrap-MS and molecular dynamics.
PubMedmedium relevance
Moderate corpus alignment

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Jiangsu Hansoh Pharma
Dapagliflozin
SGLT2 inhibitor market

Commercial impact

medium

The entry of Jiangsu Hansoh Pharma could lead to increased competition, potentially impacting market share and pricing strategies for existing SGLT2 inhibitors.

Regulatory impact

medium

The submission is currently under standard review, which could influence the approval timeline and market entry strategies for competitors.

What to watch

Monitor the review progress and any subsequent approval outcomes for ANDA216119.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.